Microsoft on Track for Longest Winning Streak Since November 2023 — Data Talk
Microsoft Corporation (MSFT) is currently at $438.63, up $7.29 or 1.69%
--Would be highest close since July 23, 2024, when it closed at $444.85
--Currently up seven consecutive days; up 9.19% over this period
--Longest winning streak since Nov. 8, 2023, when it rose for nine straight trading days
--Best seven day stretch since the seven days ending Nov. 7, 2023, when it rose 9.31%
--Up 5.15% month-to-date
--Up 16.64% year-to-date
--Down 6.19% from its all-time closing high of $467.56 on July 5, 2024
--Up 33.46% from 52 weeks ago (Sept. 19, 2023), when it closed at $328.65
--Down 6.19% from its 52-week closing high of $467.56 on July 5, 2024
--Up 40.52% from its 52-week closing low of $312.14 on Sept. 26, 2023
--Traded as high as $441.85; highest intraday level since July 23, 2024, when it hit $448.39
--Up 2.44% at today's intraday high
--Seventh most active stock in the Nasdaq 100 today
--Contributed 47.89 points to the DJIA so far today
All data as of 10:26:59 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 17, 2024 10:44 ET (14:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks